Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Research & Development (2018 - 2025)

X4 Pharmaceuticals' Research & Development history spans 8 years, with the latest figure at $18.5 million for Q4 2025.

  • For Q4 2025, Research & Development fell 14.66% year-over-year to $18.5 million; the TTM value through Dec 2025 reached $72.7 million, down 10.93%, while the annual FY2025 figure was $72.7 million, 10.93% down from the prior year.
  • Research & Development reached $18.5 million in Q4 2025 per XFOR's latest filing, up from $17.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $22.1 million in Q1 2023 to a low of $12.1 million in Q1 2021.
  • Average Research & Development over 5 years is $16.9 million, with a median of $17.8 million recorded in 2025.
  • Peak YoY movement for Research & Development: skyrocketed 56.34% in 2022, then fell 19.68% in 2023.
  • A 5-year view of Research & Development shows it stood at $12.2 million in 2021, then skyrocketed by 56.34% to $19.0 million in 2022, then dropped by 19.68% to $15.3 million in 2023, then soared by 42.1% to $21.7 million in 2024, then decreased by 14.66% to $18.5 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Research & Development are $18.5 million (Q4 2025), $17.3 million (Q3 2025), and $18.4 million (Q2 2025).